Key result
Rosuvastatin and omega-3 fatty acid exposure is linked to increased serum adiponectin levels.
Why the study?
The relationship between adiponectin serum levels and risk of coronary artery disease remains controversial, and the effects of rosuvastatin and omega-3 fatty acid on adiponectin in patients with insulin resistance and CAD were unclear.
Does rosuvastatin and/or omega-3 fatty acid improve adiponectin serum levels in patients with CAD and insulin resistance?
Population
87 patients with CAD and insulin resistance of different etiology
Comparison
Rosuvastatin alone vs omega-3 fatty acid alone vs combination vs control without treatment
Design
Observational cohort study
Authors
Loading...
Rosuvastatin or omega-3 may raise adiponectin in IR-CAD; leaves open clinical benefit pending randomized trials.
Observational (n=87)
Does rosuvastatin and/or omega-3 fatty acid improve adiponectin serum levels in patients with CAD and insulin resistance?
p-value: p=< 0.01
Rosuvastatin and/or omega-3 fatty acid may provide cardiometabolic protection by increasing adiponectin serum levels in patients with CAD and insulin resistance.
Al‐kuraishy et al. (2016) conducted an observational in Coronary artery disease and insulin resistance (n=87). Rosuvastatin and/or omega-3 fatty acid vs. No previous or current treatment with rosuvastatin or omega-3 fatty acid was evaluated on Adiponectin serum levels and cardiometabolic profile (p=< 0.01). Rosuvastatin and/or omega-3 fatty acid exposure was associated with a significant increment in adiponectin serum levels (P<0.01).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: